Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Relapsed Multiple Myeloma
Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Biological: Talquetamab
Drug: Iberdomide
Drug: Dexamethasone
Procedure: Bone Marrow Biopsy

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Thomas Martin, MD

Target Recruit Count: 38

Registration Number: NCT06348108

Locations: 🇺🇸
University of Calfornia, San Francisco, San Francisco, California, United States

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Phase 2

Not yet recruiting

Conditions: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Autologous Stem Cell Transplantation

Interventions: Biological: Daratumumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2024-04-04

Last Posted Date: 2025-01-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 39

Registration Number: NCT06348147

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Phase 2

Recruiting

Conditions: Systemic Amyloidosis

Interventions: Drug: Bortezomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2024-04-02

Last Posted Date: 2024-12-30

Lead Sponsor: Jin Lu, MD

Target Recruit Count: 40

Registration Number: NCT06342466

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Ma-Spore ALL 2020 Study

Phase 2

Recruiting

Conditions: B Lymphoblastic Leukemia

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: Vincristine
Drug: Methotrexate
Drug: L-Asparaginase
Drug: Pegylated asparaginase
Drug: Erwinase
Drug: Dasatinib
Drug: Cytarabine
Drug: Imatinib
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Rituximab
Drug: Thioguanine
Drug: Doxorubicin
Drug: Fludarabine

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT06336395

Locations: 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore